Founded in 2010 with the ambition to fight cancer, Ecrins Therapeutics is also committed to delivering value to its shareholders.
We strive to convert innovative science into efficient therapeutic products – promising a high return on investment.

Company profile

Created in 2010 by ex INSERM and Université Grenoble Alpes researchers, Ecrins Therapeutics currently employs six people.

Funding:

  • Share capital €122.589
  • More than €2.8 M of non-dilutive funding obtained
  • €660K raised in 2015

Management team:

  • CEO and President: Andrei Popov, MD, PhD
  • COO: Aurelie Juhem, PhD

Investment opportunity

Investing into Ecrins Therapeutics promises a high return on investment:

  • Strong IP portfolio
  • Drug candidate aimed at treating several aggressive forms of cancer in human and veterinary oncology
  • Exit scheduled at the end of the Clinical Proof of Concept (2019)

For investor relations enquiries please contact us.

Invest directly in Ecrins Therapeutics

  • Invest in oncology innovation
  • Strong capital gain potential
  • Starting at €20k

Contact us:
investir(at)ecrins-therapeutics.com.

Our assets:

  • ET-D5 : first-in-class anti-cancer drug candidate
  • Worldwide exclusive license (WO2011107709A1 family of patents)
  • Original and efficient drug discovery platform
  • Seasoned team of managers and advisors with complementary scientific and industrial experiences

Partnerships

Ecrins Therapeutics is open to partnerships with pharmaceutical industry to implement its challenging R&D programs.